On Oct. 28, 2025, Texas Attorney General Ken Paxton filed a landmark lawsuit against Johnson & Johnson and Kenvue, alleging they “deceptively marketed” Tylenol to pregnant women despite autism risks.
The state claims millions of mothers were misled. Analysts warn the case could expose “tens of billions of dollars in damages”. With J&J’s consumer-drug unit now worth about $40 billion, the outcome may resonate nationwide.
Tylenol’s Pregnancy Risk Spotlighted
Tylenol (acetaminophen) is widely used for fever and pain, including by expectant mothers (it’s considered the safest fever reducer in pregnancy). But recent studies and government action highlight concern. The CDC reports roughly 1 in 31 U.S. children is identified with autism. That statistic looms large for parents and lawmakers.
In September 2025, the FDA warned that prenatal use “may be associated” with autism or ADHD.
Pharma Giants Under Scrutiny
Johnson & Johnson and its former consumer-health spinoff Kenvue dominate the pain-relief market. J&J (market cap ≈ $460 billion) sold Tylenol for decades; Kenvue took over post-2023 IPO.
Texas has a history of suing these giants: it secured a $158 million settlement over Risperdal marketing and a $290 million opioid settlement in 2021. Now Tylenol is on trial.
Regulators and Advocates Weigh In
Government and health groups are sending mixed signals. In Sept. 2025, the FDA announced a label change process, acknowledging evidence that acetaminophen use in pregnancy “may be associated with” autism and ADHD.
Meanwhile, professional societies urge caution. ACOG and the American Academy of Pediatrics say studies have found no proven causal link. Obstetric experts emphasize that fever itself can harm pregnancies if untreated.
Lawsuit Announced
Paxton’s Oct. 28 press conference revealed the first state lawsuit of its kind [Main Nugget]. The Texas complaint (filed in Panola County) argues J&J and Kenvue spent decades hiding Tylenol’s harms. It claims the companies “knew acetaminophen is dangerous to unborn children and young children,” yet touted Tylenol as safe.
The suit invokes Texas’s consumer-protection laws to seek damages for affected families.
Impact on Texas Families and Policy
For Texas families, the case is deeply personal. Autism diagnoses have surged in the state’s schools and communities, mirroring the 3.2% national rate. Parents of autistic children cheered the lawsuit, hoping it would bring answers.
Advocacy groups say the trial could force changes in state health policy and prescription practices. Already, Texas legislators are discussing whether to ban or restrict acetaminophen in pregnancy.
Politicians and Advocates Speak Out
Ken Paxton has cast the suit as a moral crusade. He declared, “Big Pharma betrayed America… By holding Big Pharma accountable for poisoning our people, we will help Make America Healthy Again”.
Civil rights and autism advocates have rallied alongside Paxton, sharing personal stories of children with autism. Meanwhile, opponents criticize the science. U.S. Sen. Bill Cassidy (R-La.), a physician, called the evidence “weak” and told ABC News, “I’m a doctor… the best evidence is there’s no relationship”. The debate is now a political flashpoint as well as a courtroom battle.
FDA Label Changes and State Watch
Federal regulators have begun tightening guidance. On Sept. 22, 2025, the FDA alerted doctors that acetaminophen use in pregnancy could carry neurological risks. An internal label-change process is underway. At the state level, other attorneys general are monitoring Texas’s move.
Some have promised to “evaluate our own laws” if the case succeeds.
Market Reaction and Corporate Risk
Investors reacted swiftly. On news of the Texas suit, Johnson & Johnson shares fell ~1.8% while Kenvue stock tumbled 3.8%. In fact, Kenvue stock has slid over 20% since Tylenol’s risks were spotlighted in late September. Market analysts warn that a protracted multi-state legal battle could cost the companies billions.
Executives at J&J and Kenvue have quietly raised funds for litigation and public relations. The companies’ denials — citing a global medical consensus on safety — so far have failed to calm nervous investors.
Domino Effect on National Policy
Legal experts warn this case could set off a chain reaction [Mini-Nugget] across America. The Texas filing itself notes that because “acetaminophen is used so widely… Defendants face tens of billions of dollars in damages”.
If Paxton wins or settles heavily, other states may file similar suits and demand warning labels. Industry lobbyists fear that every state attorney general would feel empowered.
The Courtroom Battle Ahead
Texas has hired Ashley Keller (of Keller Postman PLLC) to lead the case. Keller famously won a recent opioid settlement, and Texas’s complaint cites her firm’s involvement.
Meanwhile, related federal lawsuits are tied up: a New York judge in 2024 excluded plaintiffs’ autism experts as unreliable, and those appeals are pending.
Johnson & J&J’s Defense Strategy
Both companies have officially rejected Texas’s claims. Kenvue insisted in a statement that “acetaminophen is the safest pain reliever option for pregnant women as needed throughout their entire pregnancy… We are deeply concerned by the perpetuation of misinformation”.
It also vowed to “vigorously defend” the lawsuit, arguing the Texas claims “lack legal merit and scientific support”.
Ongoing Tylenol Lawsuits and Appeals
This is not Texas’s only forum for Tylenol claims. Since 2022, dozens of parents nationwide have sued J&J and Kenvue in federal court, alleging prenatal exposure caused autism. Those cases are combined in a multidistrict litigation (MDL) under Judge [name], again led by attorney Ashley Keller.
In May 2024, that federal MDL judge largely dismissed the claims (barring expert testimony) as “unproven,” and plaintiffs are appealing.
Medical Experts Weigh In
Leading physicians remain split on the evidence. The ACOG president warned that claiming Tylenol causes autism is “irresponsible” and “highly concerning” because it may discourage needed care. She emphasizes that untreated fever and pain have known fetal risks.
On Capitol Hill, Republican Sen. Bill Cassidy (an ER doctor) scoffs at the suit, saying “as a doctor… the best evidence is there’s no relationship” between acetaminophen and autism.
Political and Regulatory Fallout
Paxton’s timing aligns with his campaign: he’s challenging Sen. John Cornyn and touts this suit as part of a “Big Pharma fight”. Republicans in Congress have held hearings on acetaminophen since September. In contrast, some Democrats accuse Paxton of grandstanding on unproven claims.
Either way, the FDA’s formal label review (launched under RFK Jr.) is continuing independently. Lawmakers in other states have proposed their own investigations into Tylenol.
Global Medical Consensus
International health bodies caution against panic. FIGO (the global OB-GYN federation) published a statement saying acetaminophen “remains the safest analgesic option for pregnant women when used appropriately”. The group notes that large European studies (using sibling comparisons) have found no link to autism.
It advises clinicians to “reassure patients” and continue recommending Tylenol judiciously, since alternatives like ibuprofen are known to be unsafe in pregnancy.
Texas Joins History Book or Isolated Case?
Texas filed this suit in Panola County — a rural area where Trump won 83% of the vote. That small-town setting is now the focal point of a national story. Regardless of partisan leanings, all sides see historic stakes. If Texas succeeds here, it could embolden other states. If it fails, courts will have set a limit on such lawsuits.
For now, legal proceedings and public scrutiny are the only outcomes we can predict: drug regulators and plaintiffs’ lawyers will observe closely.
Nationwide Media Coverage and Public Debate
The Tylenol-autism saga has dominated news and social media. Reuters notes that doctors worldwide still consider acetaminophen “the best option” for treating fever in pregnancy. But headlines are full of anxiety-provoking quotes from both sides.
News outlets quote FDA reports, lawsuits, and critics (including the Kaiser poll finding many Americans uncertain about Tylenol’s safety). Public forums and doctors’ offices are abuzz with questions.
The Road Ahead: What Comes Next?
Next up is a legal marathon. Pre-trial motions and discovery in the Texas court will begin soon. The FDA will complete its safety review (its physician letter is already circulated). Johnson & Johnson and Kenvue have vowed to appeal any adverse ruling, potentially taking the case up to Texas’s Supreme Court. By then, we expect the science to have advanced too, with more studies published.
Ultimately, this saga will end with either a court ruling, a settlement, or a new regulation.